Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology presented interim results of its Phase Ib/II FB-10 trial of PB272 (neratinib) in combination with T-DMI in HER2-positive metastatic breast cancer at the 2017 AACR Annual Meeting.

Puma Biotechnology, Inc.